Answers are grounded in this paper and cite their sources.
Dravet syndrome is a severe, early childhood epileptic encephalopathy, most often associated with a mutation in the SCN1a gene characterized by drug resistance and high neurological burden. For many years treatment was limited to non-specific antiepileptic drugs, but recently new, targeted therapies have appeared, which have significantly improved the prognosis of patients. Stiripentol, modulating GABAergic transmission, has been approved as an adjuctive treatment in the treatment of Dravet syndrome, showing a significant reduction in the frequency of seizures in combination with clobazam and valproic acid. In turn, fenfluramine, acting on serotonin receptors, among others, has proven also effective. Both drugs have been approved by the FDA and EMA, constitiuting a breakthrough in the treatment of Dravet syndrome Their introduction has significantly improved the quality of life of patients and opened up new perspectives in the treatment of developmental epilepsies.
No takes yet. Share an insight, caveat, or question.
Kozon et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: